BRIEF published on 11/04/2024 at 11:51, 1 year 9 months ago Acticor Biotech: Publication of 2024 half-year financial results Biotechnology Finance Half-year Results Glenzocimab Judicial Recovery
PRESS RELEASE published on 11/04/2024 at 11:46, 1 year 9 months ago Inside Information / News release on accounts, results Acticor Biotech publishes its half-year financial results for 2024, highlighting repositioning of glenzocimab in STEMI treatment, receivership proceedings extension, and shareholder approvals Repositioning Shareholder Approvals ACTICOR BIOTECH Glenzocimab Half-year Financial Results
BRIEF published on 10/11/2024 at 17:50, 1 year 10 months ago Acticor Biotech Advances Glenzocimab in Myocardial Infarction Treatment Clinical Trials Myocardial Infarction ACTICOR BIOTECH Glenzocimab Cardiovascular Treatment
PRESS RELEASE published on 10/11/2024 at 17:45, 1 year 10 months ago Inside Information / Other news releases Acticor Biotech repositions glenzocimab in the treatment of myocardial infarction, evaluating efficacy and safety in phase 2 studies LIBERATE and GLORIA. Clinical trials aim to reduce infarct size and prevent complications Clinical Trials Phase 2b Myocardial Infarction ACTICOR BIOTECH Glenzocimab
BRIEF published on 07/09/2024 at 20:50, 2 years 1 month ago Acticor Biotech Reports 2023 Financial Results Financial Report Annual Results Capital Raising ACTICOR BIOTECH Glenzocimab
PRESS RELEASE published on 07/09/2024 at 20:45, 2 years 1 month ago Inside Information / News release on accounts, results Acticor Biotech publishes its 2023 annual results, financial highlights, and financing outlook. Annual General Meeting scheduled for September 13, 2024 Annual General Meeting Financial Highlights 2023 Annual Results ACTICOR BIOTECH Financing Outlook
BRIEF published on 05/15/2024 at 11:20, 2 years 3 months ago Results of the ACTISAVE study and future perspectives of ACTICOR BIOTECH Stroke Treatment ACTICOR BIOTECH Glenzocimab ESOC 2024 ACTISAVE Study
PRESS RELEASE published on 05/15/2024 at 11:15, 2 years 3 months ago Inside Information / Other news releases ACTICOR BIOTECH presents main results of phase 2/3 ACTISAVE study on stroke treatment at ESOC 2024, targeting specific subgroups for potential benefits Stroke Treatment ACTICOR BIOTECH ESOC 2024 ACTISAVE Study Patient Subgroups
Published on 08/27/2026 at 08:00, 1 hour 15 minutes ago Interim Results for the Three Months Ended 30 June 2026
Published on 08/27/2026 at 02:35, 6 hours 40 minutes ago Galantas Gold Reports Second Quarter 2026 Results
Published on 08/27/2026 at 02:00, 7 hours 15 minutes ago Algo Grande Copper Announces Upsizing of Private Placement
Published on 08/27/2026 at 00:05, 9 hours 10 minutes ago Kidoz Reports Record Q2 2026 Revenue, up 37%, as H1 Revenue Reaches US$6.28 Million (CAD$8.66 Million)
Published on 08/26/2026 at 23:00, 10 hours 15 minutes ago Datametrex Announces Transition to Semi-Annual Financial Reporting
Published on 08/27/2026 at 08:30, 45 minutes ago Suspension- JPMORGAN GLOBAL CORE REAL ASSETS LIMITED
Published on 08/27/2026 at 08:27, 48 minutes ago Viromed Medical AG: CEO and founder Uwe Perbandt has supported the company for years as a long-term financier
Published on 08/27/2026 at 08:25, 50 minutes ago audius significantly increases total output by 23% in the first half of the year / EBITDA Up 17% / Growth and efficiency program launched
Published on 08/26/2026 at 18:02, 15 hours 13 minutes ago Altareit: Altarea press release regarding the Primonial matter
Published on 08/26/2026 at 18:00, 15 hours 15 minutes ago Altarea: Comprehensive settlement agreement reached, ending the dispute between Altarea and the shareholders of the Praemia group (formerly Primonial group)
Published on 08/25/2026 at 17:45, 1 day 15 hours ago CEGEDIM: DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 08/25/2026 at 17:45, 1 day 15 hours ago Imerys-08-2026-information-share-capital-and-voting-rights-as-of-31-July-2026
